SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending amid anticipation for its earnings report, with the community divided between those expecting a positive surprise and others bracing for a potential sell-off. Community discussion revolves around whether the stock can beat low expectations and overcome broader market concerns. Some traders are eyeing options activity and potential for a gamma squeeze following the report.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The QQQ is experiencing significant volatility, driven by concerns around potential rate cuts and a possible overvaluation in the tech sector following earnings. Community sentiment is largely bearish, with many anticipating further declines and questioning the strength of the market. Traders are closely watching key support levels and the impact of broader market factors like cryptocurrency movements.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heavy volatility, triggering discussions around margin calls and potential bear market conditions. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, influenced by factors like crypto sell-offs and uncertainty surrounding Federal Reserve policy. Concerns about overvaluation and the impact of potential rate cuts are also driving market anxieties.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid discussions about memory pricing and potential impacts from AI-driven demand, with some traders highlighting recent analyst upgrades while others are wary of a possible pullback after the stock's significant year-to-date gains. Community members are actively debating whether the stock is overbought and due for a correction, or if it still has room to run based on strong fundamentals and growing demand.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending downwards, with the community expressing concerns over recent price drops and a lack of news regarding satellite launches. Investors are debating whether to buy the dip or cut losses, while also questioning the company's timeline for achieving revenue and profitability. Some speculate about market manipulation and broader economic factors affecting the stock's performance.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing ($BA) is trending as the community discusses the stock's recent struggles despite positive developments like settling a strike and potential FAA approval for the 777X. Concerns persist around production stability, profitability, and the overall health of the company compared to its peers in the aerospace sector. Some traders speculate about share dilution and potential manipulation as driving forces behind the stock's downward trajectory.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors digest recent earnings, a raised FY26 outlook, and the planned transfer of its stock listing to Nasdaq. Community members are discussing the stock's resilience amid a down market and speculating on potential price movements, as well as Walmart's increasing focus on technology and AI.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending due to anticipation surrounding NVDA's earnings report and its potential impact on the data center sector; the community is closely watching for any positive news that could trigger a rally. Recent price volatility and a high short interest have investors on edge, with many hoping for a significant short squeeze. Discussions also include upcoming announcements regarding senior note offerings and new hyperscaler partnerships.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing volatile trading as investors debate the sustainability of the AI-driven semiconductor rally. Community members are closely watching for a potential market correction, with some anticipating a significant drop while others remain bullish on the sector's long-term prospects. NVIDIA's upcoming earnings and overall market sentiment are expected to be key drivers for SOXL's near-term performance.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about potential double tops and the possibility of further declines, with some speculating about drops to significantly lower levels. Community sentiment is mixed, ranging from concern over losses to opportunistic buying strategies, while others reference past market cycles and potential future black swan events. Broader discussions include quantum computing threats, the influence of large holders, and the impact of macroeconomic factors.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Los Angeles Capital Management LLC Purchases Shares of 43,422 Replimune Group, Inc. $REPL

Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The...

FY2026 EPS Forecast for Replimune Group Decreased by Analyst

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2026 earnings per share (EPS) estimates for Replimune Group in a report issued on...

171,527 Shares in Replimune Group, Inc. $REPL Purchased by Candriam S.C.A.

Candriam S.C.A. acquired a new position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities...

Nan Fung Trinity HK Ltd. Makes New Investment in Replimune Group, Inc. $REPL

Nan Fung Trinity HK Ltd. purchased a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the...

<ul class="summary-bullets"><li>FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.</li><li>Prescription Drug User Fee Act decision date is set for April 10, 2026.</li><li>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4.</li></ul>Replimune Group Inc.(REPL) on Monday announced that it has cleared a major regulatory hurdle after the U.S. Food and Drug Administration (FDA) accepted its resubmitted Biologics License Application (BLA) for RP1, a treatment for advanced melanoma.The FDA has set April 10, 2026, as the Prescription Drug User Fee Act (PDUFA) target action date for this Class II resubmission.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/REPL">Replimune stock</a>&nbsp;traded over 98% higher on Monday morning and was the third most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day while message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">What Is RP1?</h2>RP1 is Replimune’s lead therapy candidate. It is derived from a modified herpes simplex virus, engineered to enhance tumor cell destruction and stimulate the body’s immune system against cancer. The therapy is designed with a fusogenic protein (GALV-GP R-) and GM-CSF to amplify both tumor-killing activity and the immune response.<blockquote>“RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma, who have progressed on PD-1 based therapy."- Sushil Patel, CEO, Replimune.</blockquote>The BLA resubmission follows several months of engagement between the company and the agency. Replimune worked to incorporate additional clinical data, detailed analyses and supporting documentation to address regulatory concerns.<h2 class="st-heading-2">What Are Analysts Saying?</h2>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4, according to TheFly. The firm sees the FDA’s quick response after a Type A meeting as an encouraging sign, suggesting the agency is open to the updated application with the new data included.Leerink analyst Jonathan Chang raised the firm’s rating to ‘Outperform’ from ‘Market Perform’ and lifted the price target to $13 from $3, expressing renewed confidence in RP1.&nbsp;Replimune stock has lost over 14% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sealsq-stock-jumps-13-today-company-s-first-chip-with-built-in-post-quantum-encryption-draws-attention/ch6CDEMR3Yn">SEALSQ Stock Jumps 13% Today: Company’s First Chip With Built-In Post-Quantum Encryption Draws Attention</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

What Is Driving Replimune Stock’s 98% Surge Today? 

FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.

Equity

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S. Food and Drug Administration. Shares of the company slumped 42% at the time of writing.The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.The company subsequently requested a meeting with the agency to push for approval of RP1. “We remain steadfastly committed to patient access while we work with the FDA to secure regulatory approval for RP1, however, without accelerated approval based on the current application, continuation of the RP1 program in advanced melanoma, including the phase 3 confirmatory trial, will not be viable,” CEO Sushil Patel said earlier this month.However, on Thursday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.replimune.com/news-releases/news-release-details/replimune-provides-update-following-type-meeting-fda">stated</a> that it had completed a meeting with the FDA on September 16 regarding the letter pertaining to the application for approval of RP1. The company stated that it is evaluating the feedback from the FDA to determine its next steps, and the path forward under the accelerated approval pathway has not yet been determined.“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” Patel reiterated on Thursday.RP1 is Replimune’s lead product candidate. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:571/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_11_25_42_AM_png_83a21ea942.webp" alt="REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="571" height="64"><figcaption>REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that a strategic review announcement is due in the coming months.<stembedurl>https://stocktwits.com/Bakhmutbull2/message/629140552</stembedurl>A more optimistic user, however, said that RP1 remains “a therapy to watch” for melanoma patients.<stembedurl>https://stocktwits.com/sousayuri/message/629114614</stembedurl>REPL stock is down by about 73% this year and by about 70% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-healthcare-reportedly-eyes-selling-stake-in-china-unit/chDcxTmR3bI">GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Replimune Stock Plunged 42% Today – Here’s Why

The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action. 

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of...

Retail&nbsp;trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral’, citing the sudden resignation of Vinay Prasad, former head of the FDA’s biologics division, as a key development that could improve the outlook for RP1, the company’s lead oncolytic immunotherapy candidate.The stock more than doubled Wednesday, closing up 101% at $7.55.Cantor analyst Li Watsek said the FDA’s Complete Response Letter (CRL) issued on July 22 for RP1 in combination with nivolumab was likely influenced by senior leadership, possibly Prasad, overruling the agency’s review team.&nbsp;Watsek sees Prasad’s exit as “removing a major obstacle” and believes the odds of RP1 receiving accelerated approval have “greatly improved.” Cantor expects Replimune shares could return to pre-CRL levels above $12 if the decision is overturned.BMO Capital analyst Evan Seigerman&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">also said</a> Prasad’s departure is a net positive for the biopharma sector, noting that a new FDA biologics director is “likely to be more permissive of innovation.” While BMO remains uncertain whether RP1 will be reconsidered, the firm expects shares to rally meaningfully on the change.<a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">Prasad stepped down</a> just two months into his role leading the FDA’s biologics division, after facing growing backlash over how he handled Sarepta’s Elevidys, the only approved gene therapy for Duchenne muscular dystrophy.Earlier this month, Prasad and FDA Commissioner Marty Makary asked Sarepta to halt shipments of Elevidys after three children who received the therapy died, including two from liver failure.&nbsp;The move ignited backlash from patient advocates and conservative media, who slammed the agency for standing in the way of what many families see as a last hope for kids battling a fatal condition.&nbsp;Replimune stated that the CRL for RP1 cited the Ignyte Phase 1/2 trial as lacking the rigor to support approval, due to heterogeneity in the patient population and concerns regarding the confirmatory study design. No safety issues were raised.&nbsp;The company plans to request a Type A meeting with the FDA to explore a path forward for accelerated approval.CEO Sushil Patel expressed surprise at the CRL, noting that the issues raised&nbsp;had not been&nbsp;discussed during the mid- and late-cycle reviews. RP1, engineered from a herpes simplex virus, is designed to directly kill tumors and trigger a systemic immune response.&nbsp;It’s the lead program in Replimune’s proprietary RPx platform, which the company believes can work&nbsp;independently or&nbsp;in conjunction with other cancer therapies.On Stocktwits, retail sentiment for Replimune was ‘extremely bullish’ late Wednesday amid a 1,038% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/REPL">Replimune’s stock</a> has declined nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around Replimune Group (REPL) surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral.’ (Photo credit: Getty Images)

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval

Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was based on trial design concerns.

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.76	--	--	N/A
Q2 '25	-$0.74	-$0.90	-21.56%	MISSED
Q1 '25	-$0.79	-$0.95	-19.57%	MISSED
Q4 '24	-$0.72	-$0.82	-14.42%	MISSED
Q3 '24	-$0.71	-$0.79	-11.88%	MISSED

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest REPL News

REPLReplimune Group Inc